Medical imaging AI software developer Subtle Medical has raised close to $10 million in a Series B+ funding round.
Investors include existing shareholders such as Fusion Fund, EnvisionX Capital, BRV Capital, Ignite Innovation, and Samsung Ventures, according to the company. With the new investment, Subtle said it plans to accelerate U.S. and global sales initiatives and expedite the launch of its new AI-driven products.
Also this month, Subtle received U.S. Food and Drug Administration clearance for its AI software that uses deep learning to generate synthetic short-tau inversion-recovery (STIR) images from already-acquired MRI T1- and T2-weighted contrast images.
